|Day Low/High||89.03 / 89.36|
|52 Wk Low/High||74.97 / 96.31|
European stocks notched solid gains Wednesday as global equity investors build on a strong U.S. corporate earnings season, European deal speculation and encouraging economic data from Japan.
Novartis missed analysts expectations with its fourth quarter earnings but launched a $5 billion share buyback program and said it may sell its Alcon eye care unit.
The weak companies could be clobbered.
Regulators say company squelched competing drug for infant seizures.
Drugmaker faced antitrust charges over 2013 Synacthen purchase.
The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.
European health care and pharmaceutical company shares were hit hard Thursday after President-elect Donald Trump accused some firms of 'getting away with murder' in his Wednesday press conference.
A selloff in crude oil proves another roadblock in the Dow Jones Industrial Average's pursuit of 20,000.
Ariad's primary drugs are leukemia treatment Iclusig and Brigatinib, an investigational drug product targeting non-small cell lung cancer.
As part of the agreement, Ionis and Akcea are eligible to receive $225 million in near-term payments.
One of the announcements include the hiring of former Novartis executive Christi Shaw to lead the biomedicines business starting April 3.
Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
The health care sector has been a miserable performer lately -- but these five health trades are bucking the trend.
Jim Cramer says he's still 'a believer' in KKR and Opko.
Stocks kept rallying right through and after this rate hike, says Jim Cramer.
There was plenty of shame to spread around, but Theranos CEO Elizabeth Holmes' loathsome mix of arrogance, incompetence and duplicity makes her the Worst CEO of 2016.
Hundreds of millions of people worldwide suffer from chronic respiratory disease. Here's how investors can profit from the companies making strides in treating COPD.
Fovista combined with the currently approved drug Lucentis failed to improve the vision of patients with wet, age-related macular degeneration compared to Lucentis alone.
A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.
Another day, another industry damaged by the president-elect's rhetoric. But these three companies are strong enough to overcome arm-twisting over drug prices.
Stocks enjoyed another strong day on Wall Street as the financial sector pushed the S&P 500 higher.
The Dow trades at an all-time high Monday as the financial and energy sectors rise.
I spent the weekend with thousands of blood disease researchers. This is what happened.
The Dow trades at an all time high Monday as crude oil climbs higher and markets shrug off potential negative effects of Italy's 'no' vote on its constitutional reform referendum.
Stock futures rise Monday as crude oil continues to climb higher and markets shrug off potential negative effects of Italy's 'no' vote on its constitutional reform referendum.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.